Cargando…
Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study
BACKGROUND: BRAF V600E-mutant colorectal cancers (CRCs) are associated with shorter survival than BRAF wild-type tumors. Therapeutic decision-making for colorectal liver metastases (CRLM) harboring this mutation remains difficult due to the scarce literature. The aim was to study a large cohort of B...
Autores principales: | Javed, Sahir, Benoist, Stéphane, Devos, Patrick, Truant, Stéphanie, Guimbaud, Rosine, Lièvre, Astrid, Sefrioui, David, Cohen, Romain, Artru, Pascal, Dupré, Aurélien, Bachet, Jean-Baptiste, de la Fouchardière, Christelle, Ploquin, Anne, Turpin, Anthony |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034502/ https://www.ncbi.nlm.nih.gov/pubmed/35461290 http://dx.doi.org/10.1186/s12957-022-02594-2 |
Ejemplares similares
-
Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study
por: Pernot, Simon, et al.
Publicado: (2020) -
BRAF(V600E) Metastatic Colorectal Cancer: Perspective from a Patient, a Caregiver, and an Oncologist
por: Gourdin, Guillaume, et al.
Publicado: (2023) -
Prognostic value of Lynch syndrome, BRAF(V600E)
, and
RAS
mutational status in dMMR/MSI‐H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts
por: Zwart, Koen, et al.
Publicado: (2023) -
Hepatic Arterial Infusion Chemotherapy With Folfirinox or Oxaliplatin Alone in Metastatic Colorectal Cancer
por: Randrian, Violaine, et al.
Publicado: (2022) -
BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)